= Emerging. More than 5 years before clinical availability. (9.82%)
= Expected to be clinically available in 1 to 4 years. (12.95%)
= Clinically available now. (22.77%)
MSACL 2018 EU : Nicolardi

MSACL 2018 EU Abstract

Topic: Microbiology

Podium Presentation in the Ether on Thursday at 15:10 (Chair: Stefan Zimmerman)

Identification and Validation of Two Peptide Markers for the Recognition of Clostridium difficile MLST-1 and MLST-11 by MALDI-MS

Simone Nicolardi (Presenter)
Leiden University Medical Center

Presenter Bio(s): Simone Nicolardi is a senior researcher at the Center for Proteomics and Metabolomics of Leiden University Medical Center (LUMC). His work focuses on the development and application of MS-based methods for clinical studies and the characterization of biomolecules.

Authors: Jeroen Corver (1,2), Jeff Sen (3), Bastian V.H. Hornung (1,2), Bart J. Mertens (4), Eric K.L. Berssenbrugge (1,2), Ingrid M.J.G. Sanders (1,2), Nitin Kumar (5), Trevor Lawley (5), Ed J. Kuijper (1,2), Paul J. Hensbergen (3), Simone Nicolardi (3)
(1) Center of Infectious Diseases, (2) Center for Microbiota Analysis and Therapy, Department Medical Microbiology, (3) Center for Proteomics and Metabolomics, (4) Department of Medical Statistics and Bioinformatics, Leiden University Medical Center 2333 ZA Leiden, Netherlands. (5) Host-Microbiota Interactions Laboratory, Wellcome Sanger Institute, Hinxton, CB10 1SA, UK


Clostridioides difficile has rapidly emerged as the main cause of antibiotic-associated diarrhoea as a consequence of colon inflammation. C. difficile infections-associated mortality can be high and spread can occur, leading to nosocomial outbreaks. Consequently, there is a need for rapid tests which not only identify the infections, but also provides insight into the relatedness of the strains. In this study, we used ultrahigh resolution MALDI-FTICR MS to generate detailed and comprehensive bacterial protein profiles and identify specific peptide markers for MLST-1 and MLST-11. The elucidation of the amino acid sequence of these markers allowed the investigation of a large publically available genome database of C. difficile MLSTs and the accurate determination of their sensitivity and specificity. A method was developed to identify the MLST-1 marker also by low resolution MALDI-TOF MS.

Financial Disclosure

Board Memberno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above: